Sugi Predict

Sugi Predict / Compounds / SCHEMBL296874

SCHEMBL296874

SCHEMBL296874

N[C@@H](Cc1cc(F)c(O)c(F)c1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 5/20 0.55
▸ HSD17B10 Q99714 5/20 0.54
▸ USP2 O75604 4/20 0.54
▸ ALOX15 P16050 3/20 0.54
▸ ADORA3 P0DMS8 3/20 0.54
▸ PTGS1 P23219 2/20 0.54
▸ KDM4E B2RXH2 2/20 0.54
▸ RECQL P46063 2/20 0.54
▸ HIF1A Q16665 2/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ PTGS2 P35354 2/20 0.54
▸ EGFR P00533 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ FYN P06241 1/20 0.54
▸ HTR2A P28223 1/20 0.54
▸ SIRT5 Q9NXA8 1/20 0.54
▸ PKM P14618 2/20 0.53
▸ ALPI P09923 1/20 0.53
▸ XIAP P98170 1/20 0.53
▸ MEN1 O00255 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296873 1.00 SLC7A5 (0.55) SLC7A5HSD17B10USP2ALOX15ADORA3
SCHEMBL5281682 0.93 SLC7A5 (0.60) SLC7A5HSD17B10USP2ALOX15ADORA3
SCHEMBL29141541 0.92 SIRT5 (0.48) SLC7A5HSD17B10USP2ALOX15ADORA3
SCHEMBL15085642 0.89 GRIA2 (0.49) SLC7A5HSD17B10USP2ALOX15ADORA3
SCHEMBL2130333 0.87 SLC7A5 (0.55) SLC7A5HSD17B10USP2ALOX15ADORA3
SCHEMBL158046 0.87 SLC7A5 (0.55) SLC7A5HSD17B10USP2ALOX15ADORA3
SCHEMBL158047 0.87 SLC7A5 (0.55) SLC7A5HSD17B10USP2ALOX15ADORA3
Hydrochloric Acid SCHEMBL1246362 0.85 SLC7A5 (0.53) SLC7A5HSD17B10USP2ALOX15ADORA3
SCHEMBL4616523 0.85 HSD17B10 (0.68) SLC7A5HSD17B10USP2ALOX15ADORA3
SCHEMBL358292 0.85 HSD17B10 (0.68) SLC7A5HSD17B10USP2ALOX15ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof RAYZEBIO, INC. (US) 2025-07-10 — — US claimed
WO-2025137441-A1 RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 — — WO claimed
CN-104004723-B 3,5-bis-fluoro tyrosine translation system and application thereof 中国科学院生物物理研究所 2016-08-17 — — CN claimed
CN-105420203-A Tyrosine analogue translation system and gene-encoded protein photoinduced electron transfer fluorescence sensor protein family INST OF BIOPHYSICS CHINESE ACAD OF SCIENCES 2016-03-23 — — CN claimed
CN-104004723-A 3,5-difluoro-tyrosine translation system and application thereof INST BIOPHYSICS CN ACAD SCI 2014-08-27 — — CN claimed
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof RAYZEBIO, INC. (US) 2025-07-10 — — US disclosed
WO-2025137443-A1 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 — — WO disclosed
WO-2025137441-A1 RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 — — WO disclosed
CN-117279889-B Substituted fluorosulfates and uses thereof 深圳湾实验室 2025-04-25 — — CN disclosed
CN-118290691-A Bio-based antibacterial self-repairing medical polyurethane and preparation method thereof 陕西科技大学 2024-07-05 — — CN disclosed
CN-117279889-A Substituted fluorosulfates and uses thereof 深圳湾实验室 2023-12-22 — — CN disclosed
WO-2023208081-A1 SUBSTITUTED FLUOROSULFATE AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-11-02 — — WO disclosed
US-6436640-B1 DETECTING NUCLEIC ACID SEQUENCE OR MUTATION BY HYBRIDIZATION WITH LOCK NUCLEOSIDE ANALOGUE(LNA) MODIFIED OLIGONUCLEOTIDE; DIAGNOSING GENETIC DISORDERS EXIQON A/S (DK) 2002-08-20 — — US disclosed
US-20020068708-A1 OLIGONUCLEOTIDE ANALOGUES EXIQON A/S (DK) 2002-06-06 — — US disclosed
EP-1161681-A2 USE OF LNA IN MASS SPECTROMETRY Exiqon A/S (DK) 2001-12-12 — — EP disclosed
WO-2000057180-A2 USE OF LNA IN MASS SPECTROMETRY EXIQON A/S (DK) 2000-09-28 — — WO disclosed
EP-1015469-A2 BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES Exiqon A/S (DK) 2000-07-05 — — EP disclosed
WO-1999014226-A2 BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES EXIQON A/S (DK) 1999-03-25 — — WO disclosed
EP-0828709-A1 NOVEL PHYSICALLY FUNCTIONAL MATERIALS FORSKNINGSCENTER RISO (DK) 1998-03-18 — — EP disclosed
WO-1996038410-A1 NOVEL PHYSICALLY FUNCTIONAL MATERIALS Forskningscenter Risø (DK) 1996-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068708-A1 OLIGONUCLEOTIDE ANALOGUES DCLRE1B, TARBP1, NCL SLC7A5 908/4885HSD17B10 4344/4885USP2 4677/4885
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof SSTR2, SSTR4, SSTR5 SLC7A5 286/4885HSD17B10 4794/4885USP2 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.